Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$41.15 USD
-0.76 (-1.81%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $41.14 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Tarsus Pharmaceuticals, Inc.'s return on equity, or ROE, is -39.72% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that TARS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TARS 41.15 -0.76(-1.81%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Other News for TARS
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result
Short Report: Grindr shorts at record highs as CFO quits before earnings
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | TARS ...
ClearBridge Small Cap Strategy Q2 2025 Commentary